
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5197921/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal, 2020, 41, 111-188.	2.2	4,871
2	Oxidative Stress Is Progressively Enhanced With Advancing Stages of CKD. American Journal of Kidney Diseases, 2006, 48, 752-760.	1.9	328
3	Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atherosclerosis Supplements, 2002, 3, 57-68.	1.2	274
4	The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism: Clinical and Experimental, 2017, 71, 17-32.	3.4	208
5	PAF-Degrading Acetylhydrolase Is Preferentially Associated With Dense LDL and VHDL-1 in Human Plasma. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 1764-1773.	2.4	193
6	Î <b>¤</b> e role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2009, 1791, 327-338.	2.4	139
7	The pathway of neutrophil extracellular traps towards atherosclerosis and thrombosis. Atherosclerosis, 2019, 288, 9-16.	0.8	103
8	Amyloid-Beta (1-40) and the Risk of Death From Cardiovascular Causes in Patients With Coronary Heart Disease. Journal of the American College of Cardiology, 2015, 65, 904-916.	2.8	91
9	High on treatment platelet reactivity to aspirin and clopidogrel in ischemic stroke: A systematic review and meta-analysis. Journal of the Neurological Sciences, 2017, 376, 112-116.	0.6	77
10	Pathophysiological Role and Clinical Significance of Lipoprotein-Associated Phospholipase A <sub>2</sub> (Lp-PLA <sub>2</sub> ) Bound to LDL and HDL. Current Pharmaceutical Design, 2014, 20, 6256-6269.	1.9	55
11	Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia. Journal of Lipid Research, 2012, 53, 1670-1678.	4.2	53
12	Lipoprotein-Associated Phospholipase A2 Bound on High-Density Lipoprotein Is Associated With Lower Risk for Cardiac Death in Stable Coronary Artery Disease Patients. Journal of the American College of Cardiology, 2012, 60, 2053-2060.	2.8	52
13	PAF-acetylhydrolase activity on Lp(a) before and during Cu2+-induced oxidative modification in vitro. Atherosclerosis, 1996, 125, 121-134.	0.8	46
14	Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives. Expert Review of Clinical Pharmacology, 2012, 5, 319-336.	3.1	44
15	Reduced PAF-acetylhydrolase activity associated with Lp(a) in patients with coronary artery disease. Atherosclerosis, 2004, 177, 193-201.	0.8	43
16	Pleiotropic effects of apolipoprotein C3 on HDL functionality and adipose tissue metabolic activity. Journal of Lipid Research, 2017, 58, 1869-1883.	4.2	36
17	Ezetimibe Treatment Lowers Indicators of Oxidative Stress in Hypercholesterolemic Subjects with High Oxidative Stress. Lipids, 2011, 46, 341-348.	1.7	30
18	SARS-CoV-2 infection and thrombotic complications: a narrative review. Journal of Thrombosis and Thrombolysis, 2021, 52, 111-123.	2.1	30

#	Article	IF	CITATIONS
19	Platelet-activating factor acetylhydrolase and transacetylase activities in human plasma low-density lipoprotein. Biochemical Journal, 2001, 357, 457-464.	3.7	29
20	Effect of synthetic peptides corresponding to residues 313-332 of the αIIb subunit on platelet activation and fibrinogen binding to αIIbβ3. FEBS Journal, 2004, 271, 855-862.	0.2	26
21	Oxidized phospholipids and lipoprotein-associated phospholipase A2 as important determinants of Lp(a) functionality and pathophysiological role. Journal of Biomedical Research, 2018, 32, 13.	1.6	25
22	Inflammation, Oxidative Stress, Vascular Aging and Atherosclerotic Ischemic Stroke. Current Medicinal Chemistry, 2022, 29, 5496-5509.	2.4	25
23	Short- and long-term elevation of autoantibody titers against oxidized LDL in patients with acute coronary syndromes. Atherosclerosis, 2008, 196, 289-297.	0.8	22
24	Nonhemostatic Activities of Factor Xa: Are There Pleiotropic Effects of Anti-FXa Direct Oral Anticoagulants?. Angiology, 2019, 70, 896-907.	1.8	22
25	Anti-Cancer Properties of Stevia rebaudiana; More than a Sweetener. Molecules, 2022, 27, 1362.	3.8	22
26	Smoking induces lipoprotein-associated phospholipase A2 in cardiovascular disease free adults: The ATTICA Study. Atherosclerosis, 2009, 206, 303-308.	0.8	21
27	Platelet aggregatory response to platelet activating factor (PAF), ex vivo, and PAF-acetylhydrolase activity in patients with unstable angina: effect of c7E3 Fab (abciximab) therapy. Cardiovascular Research, 1999, 43, 183-191.	3.8	20
28	Alterations of Paraoxonase and Platelet-Activating Factor Acetylhydrolase Activities in Patients on Peritoneal Dialysis. Peritoneal Dialysis International, 2004, 24, 580-589.	2.3	20
29	Plasma levels of lipoprotein-associated phospholipase A2 are increased in patients with β-thalassemia. Journal of Lipid Research, 2010, 51, 3331-3341.	4.2	20
30	Lipoprotein-associated phospholipase A2 and arterial stiffness evaluation in patients with inflammatory bowel diseases. Journal of Crohn's and Colitis, 2014, 8, 936-944.	1.3	20
31	1-O-Alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (PAF) is a minor lipid component inTetrahymena pyriformiscells. FEBS Letters, 1986, 208, 52-55.	2.8	19
32	The platelet hyporesponsiveness to clopidogrel in acute coronary syndrome patients treated with 75 mg/day clopidogrel may be overcome within 1 month of treatment. Platelets, 2012, 23, 121-131.	2.3	18
33	Therapeutic Modulation of Lipoprotein-associated Phospholipase A2 (Lp-PLA2). Current Pharmaceutical Design, 2011, 17, 3656-3661.	1.9	17
34	Effects of increased body weight and short-term weight loss on serum PCSK9 levels – a prospective pilot study. Archives of Medical Sciences Atherosclerotic Diseases, 2017, 2, 46-51.	1.0	17
35	Inflammatory Biomarkers and Cardiovascular Risk Assessment. Current Knowledge and Future Perspectives. Current Pharmaceutical Design, 2013, 19, 3827-3840.	1.9	16
36	A PAF-acetylhydrolase activity inTetrahymena pyriformiscells. FEBS Letters, 1991, 288, 147-150.	2.8	15

#	Article	IF	CITATIONS
37	Deconvoluting the Dual Antiplatelet Activity of a Plant Extract. Journal of Agricultural and Food Chemistry, 2016, 64, 4511-4521.	5.2	13
38	Tailoring naringenin conjugates with amplified and triple antiplatelet activity profile: Rational design, synthesis, human plasma stability and in vitro evaluation. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 2609-2618.	2.4	13
39	Clopidogrel Generic Formulations in the Era of New Antiplatelets: A Systematic Review. Current Vascular Pharmacology, 2013, 12, 766-777.	1.7	13
40	Inhibition by cardiolipins of platelet-activating factor-induced rabbit platelet activation. Lipids, 1993, 28, 1119-1124.	1.7	12
41	Pharmacology of PCSK9 Inhibitors: Current Status and Future Perspectives. Current Pharmaceutical Design, 2019, 24, 3622-3633.	1.9	12
42	Effect of combined vitamin D administration plus dietary intervention on oxidative stress markers in patients with metabolic syndrome: AÂpilot randomized study. Clinical Nutrition ESPEN, 2019, 29, 198-202.	1.2	12
43	Association between PCSK9 Levels and Markers of Inflammation, Oxidative Stress, and Endothelial Dysfunction in a Population of Nondialysis Chronic Kidney Disease Patients. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-8.	4.0	12
44	Antiplatelet Agents and Anticoagulants: From Pharmacology to Clinical Practice. Current Pharmaceutical Design, 2017, 23, 1279-1293.	1.9	12
45	Effect of clopidogrel besylate on platelet reactivity in patients with acute coronary syndromes. Comparison with clopidogrel hydrogen sulfate. Expert Opinion on Pharmacotherapy, 2012, 13, 149-158.	1.8	11
46	Efficacy and Safety of Adjunctive Cilostazol to Clopidogrelâ€Treated Diabetic Patients With Symptomatic Lower Extremity Artery Disease in the Prevention of Ischemic Vascular Events. Journal of the American Heart Association, 2021, 10, e018184.	3.7	11
47	Effect of rosuvastatin or its combination with omega-3 fatty acids on circulating CD34 + progenitor cells and on endothelial colony formation in patients with mixed dyslipidaemia. Atherosclerosis, 2016, 251, 240-247.	0.8	10
48	Inhibition of platelet activation by peptide analogs of theβ3-intracellular domain of platelet integrinαIIbβ3conjugated to the cell-penetrating peptide Tat(48–60). Platelets, 2009, 20, 539-547.	2.3	9
49	Vitamin D status and cardiometabolic risk factors in Greek adolescents with obesity – the effect of vitamin D supplementation: a pilot study. Archives of Medical Sciences Atherosclerotic Diseases, 2020, 5, 64-71.	1.0	9
50	Transcriptional Profiling of Tumorspheres Reveals TRPM4 as a Novel Stemness Regulator in Breast Cancer. Biomedicines, 2021, 9, 1368.	3.2	9
51	Oxidized phospholipids and lipoprotein(a): An update. European Journal of Clinical Investigation, 2022, 52, e13710.	3.4	9
52	Comparative Antioxidant Effectiveness of White and Red Wine and Their Phenolic Extracts Towards Low-Density Lipoprotein Oxidation. Food Biotechnology, 2005, 19, 1-14.	1.5	8
53	The Effect of Rosuvastatin on Low-Density Lipoprotein Subfractions in Patients With Impaired Fasting Glucose. Journal of Cardiovascular Pharmacology and Therapeutics, 2015, 20, 276-283.	2.0	8
54	Factor Xa and thrombin induce endothelial progenitor cell activation. The effect of direct oral anticoagulants. Platelets, 2021, 32, 807-814.	2.3	8

#	Article	IF	CITATIONS
55	Taking action: European Atherosclerosis Society targets the United Nations Sustainable Development Goals 2030 agenda to fight atherosclerotic cardiovascular disease in Europe. Atherosclerosis, 2021, 322, 77-81.	0.8	8
56	Combining Rosuvastatin With Angiotensin-Receptor Blockers of Different PPARÎ <sup>3</sup> -Activating Capacity. Angiology, 2015, 66, 36-42.	1.8	7
57	Interleukin-17A Triggers the Release of Platelet-Derived Factors Driving Vascular Endothelial Cells toward a Pro-Angiogenic State. Cells, 2021, 10, 1855.	4.1	7
58	Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Hormones, 2016, 15, 8-14.	1.9	7
59	Salts of Clopidogrel: Investigation to Ensure Clinical Equivalence: A 12-Month Randomized Clinical Trial. Journal of Cardiovascular Pharmacology and Therapeutics, 2016, 21, 516-525.	2.0	6
60	Comparative Anti-Platelet Profiling Reveals a Potent Anti-Aggregatory Effect of CD34+ Progenitor Cell-Derived Late-Outgrowth Endothelial Cells in vitro. Journal of Vascular Research, 2018, 55, 13-25.	1.4	6
61	Circulating progenitor cells and their interaction with platelets in patients with an acute coronary syndrome. Platelets, 2019, 30, 314-321.	2.3	5
62	Autoantibodies to ox-LDL in Sjögren's syndrome: are they atheroprotective?. Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 61-67.	0.8	5
63	Designing Natural Product Hybrids Bearing Triple Antiplatelet Profile and Evaluating Their Human Plasma Stability. Methods in Molecular Biology, 2018, 1824, 371-385.	0.9	4
64	The Effect of Platelet-Rich Plasma on Endothelial Progenitor Cell Functionality. Angiology, 2021, 72, 776-786.	1.8	4
65	Urine 8-Hydroxyguanine (8-OHG) in Patients Undergoing Surgery for Colorectal Cancer. Journal of Investigative Surgery, 2022, 35, 591-597.	1.3	4
66	Acute and long-term antiplatelet therapy. Drugs of Today, 2008, 44, 331.	1.1	4
67	A highly constrained cyclic (S,S)-CDC- peptide is a potent inhibitor of carotid artery thrombosis in rabbits. Platelets, 2011, 22, 361-370.	2.3	3
68	Plasma VEGF and IL-8 Levels in Patients with Mixed Dyslipidaemia. Effect of Rosuvastatin Monotherapy or its Combination at a Lower Dose with Omega-3 Fatty Acids: A Pilot Study. Current Vascular Pharmacology, 2016, 14, 474-480.	1.7	3
69	Dynamic platelet adhesion in patients with an acute coronary syndrome: The effect of antiplatelet therapy. Platelets, 2016, 27, 812-820.	2.3	3
70	<p>Molecular Requirements for the Expression of Antiplatelet Effects by Synthetic Structural Optimized Analogues of the Anticancer Drugs Imatinib and Nilotinib</p> . Drug Design, Development and Therapy, 2019, Volume 13, 4225-4238.	4.3	3
71	Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial. Current Vascular Pharmacology, 2015, 13, 809-818.	1.7	3
72	Increased Benefit With Vorapaxar Use in Patients With a History of Myocardial Infarction and Diabetes Mellitus. Journal of Cardiovascular Pharmacology and Therapeutics, 2017, 22, 133-141.	2.0	2

#	Article	IF	CITATIONS
73	Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Î <sup>r</sup> Randomised Clinical Trial. Current Vascular Pharmacology, 2019, 17, 635-643.	1.7	2
74	FP372PCSK9 AND INDICES OF CARDIOVASCULAR MORBIDITY IN PATIENTS WITH CHRONIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	1
75	Mechanisms of platelet activation and modification of response to antiplatelet agents. Hellenic Journal of Cardiology, 2011, 52, 128-40.	1.0	1
76	Cilostazol-based triple antiplatelet therapy in the era of generic clopidogrel and new potent antiplatelet agents. Current Medical Research and Opinion, 2014, 30, 51-54.	1.9	0
77	Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation. Angiology, 2016, 67, 208-211.	1.8	0
78	Clopidogrel Therapy in Patients with Cardiovascular Disease Undergoing Transurethral Resection of the Prostate: A Step Towards Individualization. Drugs and Aging, 2017, 34, 917-923.	2.7	0
79	MO474PCSK9 LEVELS AND MARKERS OF INFLAMMATION, OXIDATIVE STRESS AND ENDOTHELIAL DYSFUNCTION IN A POPULATION OF NON-DIALYSIS CHRONIC KIDNEY DISEASE PATIENTS: IS THERE AN ASSOCIATION?. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0